<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04625907</url>
  </required_header>
  <id_info>
    <org_study_id>RG_17-247</org_study_id>
    <secondary_id>2018-000515-24</secondary_id>
    <secondary_id>45535982</secondary_id>
    <nct_id>NCT04625907</nct_id>
  </id_info>
  <brief_title>FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma</brief_title>
  <acronym>FaR-RMS</acronym>
  <official_title>FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Birmingham</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      FaR-RMS is an over-arching study for children and adults with newly diagnosed and relapsed&#xD;
      rhabdomyosarcoma (RMS)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      FaR-RMS is an over-arching study for children and adults with newly diagnosed and relapsed&#xD;
      rhabdomyosarcoma (RMS). It is a multi-arm, multi-stage format, involving several different&#xD;
      trial questions. FaR-RMS is intended to be a rolling programme of research with new treatment&#xD;
      arms being introduced dependant on emerging data and innovation. This study has multiple&#xD;
      aims. It aims to evaluate the impact of new agent regimens in both newly diagnosed and&#xD;
      relapsed RMS; whether changing the duration of maintenance therapy affects outcome; and&#xD;
      whether changes to dose, extent (in metastatic disease) and timing of radiotherapy improve&#xD;
      outcome and quality of life. In addition the study will evaluate risk stratification through&#xD;
      the use of PAX-FOXO1 fusion gene status instead of histological subtyping and explore the use&#xD;
      of FDG PET-CT response assessment as a prognostic biomarker for outcome following induction&#xD;
      chemotherapy.&#xD;
&#xD;
      Newly diagnosed patients should, where possible, be entered into the FaR-RMS study at the&#xD;
      time of first diagnosis prior to receiving any chemotherapy. However, patients can enter at&#xD;
      the point of radiotherapy or maintenance, and those with relapsed disease can enter the study&#xD;
      even if not previously entered at initial diagnosis. Patients may be entered into more than&#xD;
      one randomisation/registration, dependant on patient risk group and disease status.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 17, 2020</start_date>
  <completion_date type="Anticipated">June 2030</completion_date>
  <primary_completion_date type="Anticipated">June 2030</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event Free Survival (RT2)</measure>
    <time_frame>From randomisation to first failure event, timeframe 36 months</time_frame>
    <description>Failure events are:&#xD;
Relapse or progression of existing disease, or occurrence of disease at new sites,&#xD;
Death from any cause without disease progression,&#xD;
Second malignant neoplasm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Event Free Survival (CT1A)</measure>
    <time_frame>From randomisation to first failure event, timeframe 36 months</time_frame>
    <description>Failure events are:&#xD;
Relapse or progression of existing disease, or occurrence of disease at new sites,&#xD;
Death from any cause without disease progression,&#xD;
Second malignant neoplasm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Event Free Survival (CT1B)</measure>
    <time_frame>From randomisation to first failure event, timeframe 36 months</time_frame>
    <description>Failure events are:&#xD;
Relapse or progression of existing disease, or occurrence of disease at new sites,&#xD;
Death from any cause without disease progression,&#xD;
Second malignant neoplasm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Event Free Survival (CT2A)</measure>
    <time_frame>From randomisation to first failure event, timeframe 36 months</time_frame>
    <description>Failure events are:&#xD;
Relapse or progression of existing disease, or occurrence of disease at new sites,&#xD;
Death from any cause without disease progression,&#xD;
Second malignant neoplasm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Event Free Survival (CT2B)</measure>
    <time_frame>Time from randomisation to first failure event, timeframe 36 months</time_frame>
    <description>Failure events are:&#xD;
Relapse or progression of existing disease, or occurrence of disease at new sites,&#xD;
Death from any cause without disease progression,&#xD;
Second malignant neoplasm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Event Free Survival (CT3)</measure>
    <time_frame>Time from randomisation to first failure event, timeframe 36 months</time_frame>
    <description>Failure events are:&#xD;
Relapse or progression of existing disease, or occurrence of disease at new sites,&#xD;
Death from any cause without disease progression,&#xD;
Second malignant neoplasm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Local Failure Free Survival (RT1A and RT1B)</measure>
    <time_frame>Time from randomisation to first local failure event, timeframe 36 months</time_frame>
    <description>A local failure event is relapse or progression of tumour at the primary site at any time even if there has been a prior /concurrent, regional or distant failure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Local Failure Free Survival (RT1C)</measure>
    <time_frame>Time from randomisation to first local failure event, timeframe 36 months</time_frame>
    <description>A local failure event is relapse or progression of tumour at the primary site at any time even if there has been a prior /concurrent, regional or distant failure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recommended Phase II Dose (Phase 1b)</measure>
    <time_frame>From first patient first visit in dose finding study until appropriate dose level found, estimated 9 months</time_frame>
    <description>Based on tolerability, where tolerability is evaluated through the occurrence of dose limiting toxicity (DLT).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Tolerated Dose (Phase 1b)</measure>
    <time_frame>From first patient first visit in dose finding study until appropriate dose level</time_frame>
    <description>Dose level at which no or one participant experiences a DLT when at least two of three to six participants experience a DLT at the next highest dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity (All chemotherapy randomisations)</measure>
    <time_frame>From date of protocol defined treatment until 30 days after the administration of the last treatment</time_frame>
    <description>Categorised and graded using Common Terminology Criteria for Adverse Events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose Limiting Toxicity (Phase 1b)</measure>
    <time_frame>From commencement of treatment until 21 days after the start of cycle 2 (each cycle is 21 days)</time_frame>
    <description>Diarrhoea: Grade 3 for &gt;3 days despite loperamide therapy Diarrhoea: Grade 4 despite loperamide therapy. Enterocolitis: Grade 3 or above Ileus: Grade 3 or above for more than 3 days Oral mucositis: Grade 3 above for &gt;3 days despite optimal supportive care Persistent neutropenia or thrombocytopenia leading to delay of start of next course by &gt;7 days; i.e. starting &gt; day 28 Any grade 3 or 4 toxicity resulting in discontinuation of the new combination Any grade 5 toxicity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response (Phase 1b, CT1A, CT1B)</measure>
    <time_frame>Response assessed after course 3 (63 days) and 6 (126 days)</time_frame>
    <description>defined as complete (CR) or partial response (PR) and is clinically defined. Patients who are not assessable for response - e.g. because of early stopping of treatment or death - will be assumed to be non-responders.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response (CT3)</measure>
    <time_frame>Response assessed after cycle 2 and 4 (each cycle is 21 days)</time_frame>
    <description>defined as complete (CR) or partial response (PR) and is clinically defined. Patients who are not assessable for response - e.g. because of early stopping of treatment or death - will be assumed to be non-responders.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (CT1A)</measure>
    <time_frame>From randomisation to death from any cause, assessed for 36 months</time_frame>
    <description>Death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (CT1B)</measure>
    <time_frame>From randomisation to death from any cause, assessed for 36 months</time_frame>
    <description>Death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (CT2A)</measure>
    <time_frame>From randomisation to death from any cause, assessed for 36 months</time_frame>
    <description>Death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (CT2B)</measure>
    <time_frame>From randomisation to death from any cause, assessed for 36 months</time_frame>
    <description>Death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (RT1A and RT1B)</measure>
    <time_frame>From randomisation to death from any cause, assessed for 36 months</time_frame>
    <description>Death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (RT1C)</measure>
    <time_frame>From RT1C randomisation to death from any cause, assessed for 36 months</time_frame>
    <description>Death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (RT2)</measure>
    <time_frame>From RT2 randomisation to death from any cause, as assessed for 36 months</time_frame>
    <description>Death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (CT3)</measure>
    <time_frame>From randomisation to death from any cause, assessed for 36 months</time_frame>
    <description>Death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (all patients)</measure>
    <time_frame>From randomisation/registration to death from any cause, assessed for 36 months</time_frame>
    <description>Death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute wound complications and post-operative complications (RT1A and RT1B)</measure>
    <time_frame>Within 120 days from surgery</time_frame>
    <description>specific grade 3 and above complications according to CTCAE v 4 and Clavien Dindo scale. Specific wound complications within the same time frame will also be collected</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute post-radiotherapy complications (All radiotherapy randomisations)</measure>
    <time_frame>Within 120 days from start of radiotherapy</time_frame>
    <description>any grade 3 and above event according to CTCAE v 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late complications (RT1A, RT1B. RT1C)</measure>
    <time_frame>After 120 days from last local therapy</time_frame>
    <description>specific grade 3 and above events according to CTCAE and Clavien-Dindo scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Loco-regional failure-free survival (All radiotherapy randomisations)</measure>
    <time_frame>From randomisation to first local and/or regional failure event, assessed for 36 months</time_frame>
    <description>A local failure event is relapse or progression of tumour at the primary site at any time even if there has been a prior concurrent local, regional or distant failure. A regional event is relapse or progression of tumour at regional lymph nodes at any time even if there has been a prior distant failure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health related quality of life (RT1A and RT2)</measure>
    <time_frame>4 timepoints: 1) 1 day of start of radiotherapy, 2) at completion of radiotherapy, average 5 weeks after start of radiotherapy, 3) 3 months and 4) 24 months following radiotherapy</time_frame>
    <description>will be assessed using PedsQL for the paediatric population (under 18 years) and EORTC QLQ-C30 for patients 18 years of age and over</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Response (CT3)</measure>
    <time_frame>Throughout the treatment for CT3, for 12 cycles (each cycle is 21 days)</time_frame>
    <description>Best Response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (CT3)</measure>
    <time_frame>From the date of first response to date of relapse, progression or death from any cause, assessed for 36 months</time_frame>
    <description>Duration of response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PET Response (if participating in PET Sub-study)</measure>
    <time_frame>After three cycles of chemotherapy (each cycle is 21 days)</time_frame>
    <description>assessed by PERCIST criteria and visual 'Deauville like' criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event Free Survival (all patients)</measure>
    <time_frame>From date of randomisation/registration to death from any cause, assessed for 36 months</time_frame>
    <description>Failure events are:&#xD;
Relapse or progression of existing disease, or occurrence of disease at new sites,&#xD;
Death from any cause without disease progression,&#xD;
Second malignant neoplasm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event Free Survival (if participating in PET Sub-study)</measure>
    <time_frame>From date of randomisation/registration to death from any cause, assessed for 36 months</time_frame>
    <description>Failure events are:&#xD;
Relapse or progression of existing disease, or occurrence of disease at new sites,&#xD;
Death from any cause without disease progression,&#xD;
Second malignant neoplasm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local Failure Free Survival (if participating in PET Sub-study)</measure>
    <time_frame>From date of randomisation/registration to first local failure event, assessed for 36 months</time_frame>
    <description>A local failure event is relapse or progression of tumour at the primary site at any time even if there has been a prior /concurrent, regional or distant failure</description>
  </secondary_outcome>
  <number_of_arms>19</number_of_arms>
  <enrollment type="Anticipated">1672</enrollment>
  <condition>Rhabdomyosarcoma</condition>
  <arm_group>
    <arm_group_label>Phase 1b Dose finding: VHR induction - IRIVA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Irinotecan: an i.v. infusion over 1 hour on days 8,9,10,11 and 12 . For the phase 1b registration, starting dose of 20 mg/m2.&#xD;
Ifosfamide: 3g/m2 as an i.v. infusion over 3 hours on days 1 and 2 Vincristine: 1.5 mg/m2 as an i.v. bolus injection (maximum dose 2mg). Administered days 1,8,15 on cycles 1-2 and on days 1 and 8 on cycles 3-9.&#xD;
Actinomycin: 1.5 mg/m2 as an i.v. bolus injection (maximum dose 2mg) on day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CT1A: VHR induction - IVADO</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ifosfamide: 3g/m2 as an i.v. infusion over 3 hours on days 1 and 2 Vincristine: 1.5 mg/m2 as an i.v. bolus (maximum dose 2mg). Administered days 1,8,15 on cycles 1-2 and on day 1 on cycles 3-9.&#xD;
Actinomycin: 1.5 mg/m2 as an i.v. bolus injection (maximum dose 2mg) on day 1. Doxorubicin: 30 mg/m2 as an i.v infusion over 1 hour on days 1 and 2 on cycles 1-4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CT1A: VHR Induction IRIVA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Irinotecan: an i.v. infusion over 1 hour on days 8,9,10,11 and 12 . Phase 2 recommended dose as determined by IRIVA dose finding arm Ifosfamide: 3g/m2 as an i.v. infusion over 3 hours on days 1 and 2 Vincristine: 1.5 mg/m2 as an i.v. bolus injection (maximum dose 2mg). Administered days 1,8,15 on cycles 1-2 and on days 1 and 8 on cycles 3-9.&#xD;
Actinomycin: 1.5 mg/m2 as an i.v. bolus injection (maximum dose 2mg) on day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CT1B: HR Induction IVA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ifosfamide: 3g/m2 as an i.v. infusion over 3 hours on days 1 and 2 Vincristine: 1.5 mg/m2 as an i.v. bolus injection (maximum dose 2mg). Administered days 1,8,15 on cycles 1-2 and on day 1 on cycles 3-9.&#xD;
Actinomycin: 1.5 mg/m2 as an i.v. bolus injection (maximum dose 2mg) on day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CT1B: HR Induction IRIVA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Irinotecan: an i.v. infusion over 1 hour on days 8,9,10,11 and 12 . Phase 2 recommended dose as determined by IRIVA dose finding arm Ifosfamide: 3g/m2 as an i.v. infusion over 3 hours on days 1 and 2 Vincristine: 1.5 mg/m2 as an i.v. bolus injection (maximum dose 2mg). Administered days 1,8,15 on cycles 1-2 and on days 1 and 8 on cycles 3-9.&#xD;
Actinomycin: 1.5 mg/m2 as an i.v. bolus injection (maximum dose 2mg) on day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RT1A: Preoperative Radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To be given either 41.4 Gy or 50.4 Gy prior to surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RT1A: Post operative radiotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>To be given either 41.4 Gy or 50.4 Gy following surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RT1B: Radiotherapy for resectable disease: dose escalated</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To receive 50.4 Gy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RT1B: Radiotherapy for resectable disease: standard dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>To receive 41.4 Gy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RT1C: Radiotherapy for unresectable disease: dose escalated</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To receive 59.4 Gy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RT1C: Radiotherapy for unresectable disease: standard dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>To receive 50.4 Gy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RT2: Radiotherapy to primary tumour and involved lymph nodes</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiotherapy to the primary tumour and involved regional lymph nodes only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RT2: Radiotherapy to all metastatic sites</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiotherapy given to all metastatic sites</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CT2A: VHR Maintenance - VC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vinorelbine: 25 mg/m2 i.v. or 60 mg/m2 orally on days 1,8 and 15 Cyclophosphamide 25 mg/m2 orally daily for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CT2A: Maintenance -Stop treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>To stop treatment at the point of randomisation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CT2B: HR Maintenance - VC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vinorelbine: 25 mg/m2 i.v. on days 1,8 and 15 Cyclophosphamide 25 mg/m2 orally daily for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CT2B: HR Maintenance - Stop Treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>To stop treatment at the point of randomisation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Relpased Chemotherapy - VIR</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vincristine: 1.5 mg/m2 as an i.v. bolus injection (maximum dose 2mg) on days 1 and 8 Irinotecan: 50 mg/m2 as an i.v. infusion over 1 hour on days 1-5</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Relapsed Chemotherapy - VIRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vincristine: 1.5 mg/m2 as an i.v. bolus injection (maximum dose 2mg) on days 1 and 8 Irinotecan: 50 mg/m2 as an i.v. infusion over 1 hour on days 1-5 Temozolomide: 125 mg/m2 given orally on days 1-5</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>antineoplastic enzyme inhibitor</description>
    <arm_group_label>CT1A: VHR Induction IRIVA</arm_group_label>
    <arm_group_label>CT1B: HR Induction IRIVA</arm_group_label>
    <arm_group_label>Phase 1b Dose finding: VHR induction - IRIVA</arm_group_label>
    <arm_group_label>Relapsed Chemotherapy - VIRT</arm_group_label>
    <arm_group_label>Relpased Chemotherapy - VIR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Actinomycin D</intervention_name>
    <description>Antineoplastic agent that is a polypeptide antibiotic</description>
    <arm_group_label>CT1A: VHR Induction IRIVA</arm_group_label>
    <arm_group_label>CT1A: VHR induction - IVADO</arm_group_label>
    <arm_group_label>CT1B: HR Induction IRIVA</arm_group_label>
    <arm_group_label>CT1B: HR Induction IVA</arm_group_label>
    <arm_group_label>Phase 1b Dose finding: VHR induction - IRIVA</arm_group_label>
    <other_name>Dactinomycin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>An anthracycline topoisomerase inhibitor isolated from streptpmyces peucetius var. casesius</description>
    <arm_group_label>CT1A: VHR induction - IVADO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ifosfamide</intervention_name>
    <description>chemotherapeutic agent chemically related to the nitrogen mustards and is a synthetic analog of cyclophosphamide</description>
    <arm_group_label>CT1A: VHR Induction IRIVA</arm_group_label>
    <arm_group_label>CT1A: VHR induction - IVADO</arm_group_label>
    <arm_group_label>CT1B: HR Induction IRIVA</arm_group_label>
    <arm_group_label>CT1B: HR Induction IVA</arm_group_label>
    <arm_group_label>Phase 1b Dose finding: VHR induction - IRIVA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>anti neoplastic vinca alkaloid agent</description>
    <arm_group_label>CT1A: VHR Induction IRIVA</arm_group_label>
    <arm_group_label>CT1A: VHR induction - IVADO</arm_group_label>
    <arm_group_label>CT1B: HR Induction IRIVA</arm_group_label>
    <arm_group_label>CT1B: HR Induction IVA</arm_group_label>
    <arm_group_label>Phase 1b Dose finding: VHR induction - IRIVA</arm_group_label>
    <arm_group_label>Relapsed Chemotherapy - VIRT</arm_group_label>
    <arm_group_label>Relpased Chemotherapy - VIR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinorelbine</intervention_name>
    <description>vinca alkaloid with a role as an antineoplastic agent</description>
    <arm_group_label>CT2A: VHR Maintenance - VC</arm_group_label>
    <arm_group_label>CT2B: HR Maintenance - VC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent</description>
    <arm_group_label>CT2A: VHR Maintenance - VC</arm_group_label>
    <arm_group_label>CT2B: HR Maintenance - VC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <description>oral antineoplastic alkylating agent</description>
    <arm_group_label>Relapsed Chemotherapy - VIRT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiotherapy</intervention_name>
    <description>Ionising radiation</description>
    <arm_group_label>RT1A: Post operative radiotherapy</arm_group_label>
    <arm_group_label>RT1A: Preoperative Radiotherapy</arm_group_label>
    <arm_group_label>RT1B: Radiotherapy for resectable disease: dose escalated</arm_group_label>
    <arm_group_label>RT1B: Radiotherapy for resectable disease: standard dose</arm_group_label>
    <arm_group_label>RT1C: Radiotherapy for unresectable disease: dose escalated</arm_group_label>
    <arm_group_label>RT1C: Radiotherapy for unresectable disease: standard dose</arm_group_label>
    <arm_group_label>RT2: Radiotherapy to all metastatic sites</arm_group_label>
    <arm_group_label>RT2: Radiotherapy to primary tumour and involved lymph nodes</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for study entry - Mandatory at first point of study entry&#xD;
&#xD;
          1. Histologically confirmed diagnosis of RMS (except pleomorphic RMS)&#xD;
&#xD;
          2. Written informed consent from the patient and/or the parent/legal guardian&#xD;
&#xD;
        Phase 1b Dose Finding - IRIVA Inclusion&#xD;
&#xD;
          1. Entered in to the FaR-RMS study at diagnosis&#xD;
&#xD;
          2. Very High Risk disease&#xD;
&#xD;
          3. Age &gt;12 months and ≤25 years&#xD;
&#xD;
          4. No prior treatment for RMS other than surgery&#xD;
&#xD;
          5. Medically fit to receive treatment&#xD;
&#xD;
          6. Adequate hepatic function:&#xD;
&#xD;
               1. Total bilirubin ≤ 1.5 times upper limit of normal (ULN) for age, unless the&#xD;
                  patient is known to have Gilbert's syndrome&#xD;
&#xD;
               2. ALT or AST &lt; 2.5 X ULN for age&#xD;
&#xD;
          7. Absolute neutrophil count ≥1.0x 109/L&#xD;
&#xD;
          8. Platelets ≥ 80 x 109/L&#xD;
&#xD;
          9. Adequate renal function: estimated or measured creatinine clearance ≥60 ml/min/1.73 m2&#xD;
&#xD;
         10. Documented negative pregnancy test for female patients of childbearing potential&#xD;
&#xD;
         11. Patient agrees to use contraception during therapy and for 12 months after last trial&#xD;
             treatment (females) or 6 months after last trial treatment (males), where patient is&#xD;
             sexually active&#xD;
&#xD;
         12. Written informed consent from the patient and/or the parent/legal guardian&#xD;
&#xD;
        Exclusion&#xD;
&#xD;
          1. Weight &lt;10kg&#xD;
&#xD;
          2. Active &gt; grade 2 diarrhoea&#xD;
&#xD;
          3. Prior allo- or autologous Stem Cell Transplant&#xD;
&#xD;
          4. Uncontrolled inter-current illness or active infection&#xD;
&#xD;
          5. Pre-existing medical condition precluding treatment&#xD;
&#xD;
          6. Urinary outflow obstruction that cannot be relieved prior to starting treatment&#xD;
&#xD;
          7. Active inflammation of the urinary bladder (cystitis)&#xD;
&#xD;
          8. Known hypersensitivity to any of the treatments or excipients&#xD;
&#xD;
          9. Second malignancy&#xD;
&#xD;
         10. Pregnant or breastfeeding women&#xD;
&#xD;
        Frontline chemotherapy randomisation Very High Risk - CT1a Inclusion&#xD;
&#xD;
          1. Entered in to the FaR-RMS study at diagnosis&#xD;
&#xD;
          2. Very High Risk disease&#xD;
&#xD;
          3. Age ≥ 6 months&#xD;
&#xD;
          4. Available for randomisation ≤60 days after diagnostic biopsy/surgery&#xD;
&#xD;
          5. No prior treatment for RMS other than surgery&#xD;
&#xD;
          6. Medically fit to receive treatment&#xD;
&#xD;
          7. Adequate hepatic function :&#xD;
&#xD;
             a. Total bilirubin ≤ 1.5 times upper limit of normal (ULN) for age, unless the patient&#xD;
             is known to have Gilbert's syndrome&#xD;
&#xD;
          8. Absolute neutrophil count ≥1.0x 109/L (except in patients with documented bone marrow&#xD;
             disease)&#xD;
&#xD;
          9. Platelets ≥ 80 x 109/L (except in patients with documented bone marrow disease)&#xD;
&#xD;
         10. Fractional Shortening ≥ 28%&#xD;
&#xD;
         11. Documented negative pregnancy test for female patients of childbearing potential&#xD;
&#xD;
         12. Patient agrees to use contraception during therapy and for 12 months after last trial&#xD;
             treatment (females) or 6 months after last trial treatment (males), where patient is&#xD;
             sexually active&#xD;
&#xD;
         13. Written informed consent from the patient and/or the parent/legal guardian&#xD;
&#xD;
        Exclusion&#xD;
&#xD;
          1. Active &gt; grade 2 diarrhoea&#xD;
&#xD;
          2. Prior allo- or autologous Stem Cell Transplant&#xD;
&#xD;
          3. Uncontrolled inter-current illness or active infection&#xD;
&#xD;
          4. Pre-existing medical condition precluding treatment&#xD;
&#xD;
          5. Urinary outflow obstruction that cannot be relieved prior to starting treatment&#xD;
&#xD;
          6. Active inflammation of the urinary bladder (cystitis)&#xD;
&#xD;
          7. Known hypersensitivity to any of the treatments or excipients&#xD;
&#xD;
          8. Second malignancy&#xD;
&#xD;
          9. Pregnant or breastfeeding women&#xD;
&#xD;
        Frontline chemotherapy randomisation High Risk - CT1b Inclusion&#xD;
&#xD;
          1. Entered in to the FaR-RMS study at diagnosis&#xD;
&#xD;
          2. High Risk disease&#xD;
&#xD;
          3. Age ≥ 6 months&#xD;
&#xD;
          4. Available for randomisation ≤60 days after diagnostic biopsy/surgery&#xD;
&#xD;
          5. No prior treatment for RMS other than surgery&#xD;
&#xD;
          6. Medically fit to receive treatment&#xD;
&#xD;
          7. Adequate hepatic function :&#xD;
&#xD;
             a. Total bilirubin ≤ 1.5 times upper limit of normal (ULN) for age, except if the&#xD;
             patient is known to have Gilbert's syndrome&#xD;
&#xD;
          8. Absolute neutrophil count ≥1.0x 109/L&#xD;
&#xD;
          9. Platelets ≥ 80 x 109/L&#xD;
&#xD;
         10. Documented negative pregnancy test for female patients of childbearing potential&#xD;
&#xD;
         11. Patient agrees to use contraception during therapy and for 12 months after last trial&#xD;
             treatment (females) or 6 months after last trial treatment (males), where patient is&#xD;
             sexually active&#xD;
&#xD;
         12. Written informed consent from the patient and/or the parent/legal guardian&#xD;
&#xD;
        Exclusion&#xD;
&#xD;
          1. Active &gt; grade 2 diarrhoea&#xD;
&#xD;
          2. Prior allo- or autologous Stem Cell Transplant&#xD;
&#xD;
          3. Uncontrolled inter-current illness or active infection&#xD;
&#xD;
          4. Pre-existing medical condition precluding treatment&#xD;
&#xD;
          5. Urinary outflow obstruction that cannot be relieved prior to starting treatment&#xD;
&#xD;
          6. Active inflammation of the urinary bladder (cystitis)&#xD;
&#xD;
          7. Known hypersensitivity to any of the treatments or excipients&#xD;
&#xD;
          8. Second malignancy&#xD;
&#xD;
          9. Pregnant or breastfeeding women&#xD;
&#xD;
        Frontline Radiotherapy Note: eligible patients may enter multiple radiotherapy&#xD;
        randomisations.&#xD;
&#xD;
        Radiotherapy Inclusion - for all radiotherapy randomisations&#xD;
&#xD;
          1. Entered in to the FaR-RMS study (at diagnosis or prior to radiotherapy randomisation)&#xD;
&#xD;
          2. Very High Risk, High Risk and Standard Risk disease&#xD;
&#xD;
          3. ≥ 2 years of age&#xD;
&#xD;
          4. Receiving frontline induction treatment as part of the FaR-RMS trial or with a&#xD;
             IVA/IVADo based chemotherapy regimen patients for whom. Note that patients for whom&#xD;
             ifosfamide has been replaced with cyclophosphamide will be eligible&#xD;
&#xD;
          5. Patient assessed as medically fit to receive the radiotherapy&#xD;
&#xD;
          6. Documented negative pregnancy test for female patients of childbearing potential&#xD;
&#xD;
          7. Patient agrees to use contraception during therapy and for 12 months after last trial&#xD;
             treatment (females) or 6 months after last trial treatment (males), where patient is&#xD;
             sexually active&#xD;
&#xD;
          8. Written informed consent from the patient and/or the parent/legal guardian&#xD;
&#xD;
        Radiotherapy Exclusion - for all radiotherapy randomisations&#xD;
&#xD;
          1. Prior allo- or autologous Stem Cell Transplant&#xD;
&#xD;
          2. Second malignancy&#xD;
&#xD;
          3. Pregnant or breastfeeding women&#xD;
&#xD;
          4. Receiving radiotherapy as brachytherapy&#xD;
&#xD;
        RT1a Specific Inclusion&#xD;
&#xD;
          1. Primary tumour deemed resectable (predicted R0/ R1 resection feasible) after 3 cycles&#xD;
             of induction chemotherapy (6 cycles for metastatic disease)&#xD;
&#xD;
          2. Adjuvant radiotherapy required in addition to surgical resection (local decision).&#xD;
&#xD;
          3. Available for randomisation after cycle 3 and prior to the start of cycle 6 of&#xD;
             induction chemotherapy for localised disease, or after cycle 6 and prior to the start&#xD;
             of cycle 9 for metastatic disease&#xD;
&#xD;
        RT1b Specific Inclusion&#xD;
&#xD;
          1. Primary tumour deemed resectable (predicted R0/R1 resection) after 3 cycles of&#xD;
             induction chemotherapy (6 cycles for metastatic disease).&#xD;
&#xD;
          2. Adjuvant radiotherapy required in addition to surgical resection (local decision)&#xD;
&#xD;
          3. Higher Local Failure Risk (HLFR) based on presence of either of the following&#xD;
             criteria:&#xD;
&#xD;
               1. Unfavourable site&#xD;
&#xD;
               2. Age ≥ 18yrs&#xD;
&#xD;
          4. Available for randomisation after cycle 3 and prior to the start of cycle 6 of&#xD;
             induction chemotherapy for localised disease, or after cycle 6 and prior to the start&#xD;
             of cycle 9 for metastatic disease&#xD;
&#xD;
        RT1c Specific Inclusion&#xD;
&#xD;
          1. Primary radiotherapy indicated (local decision)&#xD;
&#xD;
          2. Higher Local Failure Risk (HLFR) based on either of the following criteria:&#xD;
&#xD;
               1. Unfavourable site&#xD;
&#xD;
               2. Age ≥ 18yrs&#xD;
&#xD;
          3. Available for randomisation after cycle 3 and prior to the start of cycle 6 of&#xD;
             induction chemotherapy for localised disease, or after cycle 6 and prior to the start&#xD;
             of cycle 9 for metastatic disease&#xD;
&#xD;
        RT2&#xD;
&#xD;
          1. Available for randomisation after cycle 6 and before the start of cycle 9 of induction&#xD;
             chemotherapy.&#xD;
&#xD;
          2. Unfavourable metastatic disease, defined as Modified Oberlin Prognostic Score 2-4&#xD;
&#xD;
               -  Note: Definition of metastatic lesions for RT2 eligibility&#xD;
&#xD;
        Modified Oberlin Prognostic Score (1 point for each adverse factor):&#xD;
&#xD;
          -  Age ≥10y&#xD;
&#xD;
          -  Extremity, Other, Unidentified Primary Site&#xD;
&#xD;
          -  Bone and/ or Bone Marrow involvement&#xD;
&#xD;
          -  ≥3 metastatic sites&#xD;
&#xD;
        Unfavourable metastatic disease: 2- 4 adverse factors Favourable metastatic disease: 0-1&#xD;
        adverse factors&#xD;
&#xD;
        Maintenance chemotherapy (Very High Risk) - CT2a Inclusion Randomisation must take place&#xD;
        during the 12th cycle of maintenance chemotherapy.&#xD;
&#xD;
          1. Entered in to the FaR-RMS study (at diagnosis or at any subsequent time point)&#xD;
&#xD;
          2. Very High Risk disease&#xD;
&#xD;
          3. Received frontline induction chemotherapy as part of the FaR-RMS trial or with a&#xD;
             IVA/IVADo based chemotherapy regimen&#xD;
&#xD;
             a. Patients for whom ifosfamide has been replaced with cyclophosphamide will be&#xD;
             eligible&#xD;
&#xD;
          4. Completed 11 cycles of VnC maintenance treatment (either oral or IV regimens)&#xD;
&#xD;
          5. No evidence of progressive disease&#xD;
&#xD;
          6. Absence of severe vincristine neuropathy - i.e requiring discontinuation of&#xD;
             vincristine treatment)&#xD;
&#xD;
          7. Medically fit to continue to receive treatment&#xD;
&#xD;
          8. Patient agrees to use contraception during therapy and for 12 months after last trial&#xD;
             treatment (females) or 6 months after last trial treatment (males), where patient is&#xD;
             sexually active&#xD;
&#xD;
          9. Written informed consent from the patient and/or the parent/legal guardian&#xD;
&#xD;
        Exclusion&#xD;
&#xD;
          1. Prior allo- or autologous Stem Cell Transplant&#xD;
&#xD;
          2. Uncontrolled intercurrent illness or active infection&#xD;
&#xD;
          3. Urinary outflow obstruction that cannot be relieved prior to starting treatment&#xD;
&#xD;
          4. Active inflammation of the urinary bladder (cystitis)&#xD;
&#xD;
          5. Second malignancy&#xD;
&#xD;
          6. Pregnant or breastfeeding women&#xD;
&#xD;
        Maintenance chemotherapy (High Risk) - CT2b Randomisation must take place during the 6th&#xD;
        cycle of maintenance chemotherapy. Inclusion&#xD;
&#xD;
          1. Entered in to the FaR-RMS study (at diagnosis or at any subsequent time point)&#xD;
&#xD;
          2. High Risk disease&#xD;
&#xD;
          3. Received frontline induction chemotherapy as part of the FaR-RMS trial or with a IVA&#xD;
             based chemotherapy regimen. Note that patients for whom ifosfamide has been replaced&#xD;
             with cyclophosphamide will be eligible&#xD;
&#xD;
          4. Completed 5 cycles of VnC maintenance treatment&#xD;
&#xD;
          5. No evidence of progressive disease&#xD;
&#xD;
          6. Absence of severe vincristine neuropathy i.e. requiring discontinuation of vincristine&#xD;
             treatment&#xD;
&#xD;
          7. Medically fit to continue to receive treatment&#xD;
&#xD;
          8. Patient agrees to use contraception during therapy and for 12 months after last trial&#xD;
             treatment (females) or 6 months after last trial treatment (males), where patient is&#xD;
             sexually active&#xD;
&#xD;
          9. Written informed consent from the patient and/or the parent/legal guardian&#xD;
&#xD;
        Exclusion&#xD;
&#xD;
          1. Prior allo- or autologous Stem Cell Transplant&#xD;
&#xD;
          2. Uncontrolled inter current illness or active infection&#xD;
&#xD;
          3. Urinary outflow obstruction that cannot be relieved prior to starting treatment&#xD;
&#xD;
          4. Active inflammation of the urinary bladder (cystitis)&#xD;
&#xD;
          5. Second malignancy&#xD;
&#xD;
          6. Pregnant or breastfeeding women&#xD;
&#xD;
        Relapse randomisation CT3 Inclusion&#xD;
&#xD;
          1. Entered in to the FaR-RMS study (at diagnosis or at any subsequent time point&#xD;
             including at relapse)&#xD;
&#xD;
          2. Age ≥ 6 months&#xD;
&#xD;
          3. First or subsequent relapse of RMS&#xD;
&#xD;
          4. No cytotoxic chemotherapy or other investigational medicinal product (IMP) within&#xD;
             previous two weeks&#xD;
&#xD;
          5. Medically fit to receive trial treatment&#xD;
&#xD;
          6. Documented negative pregnancy test for female patients of childbearing potential&#xD;
&#xD;
          7. Patient agrees to use contraception during therapy and for 12 months after last trial&#xD;
             treatment (females) or 6 months after last trial treatment (males), where patient is&#xD;
             sexually active&#xD;
&#xD;
          8. Written informed consent from the patient and/or the parent/legal guardian&#xD;
&#xD;
        Exclusion&#xD;
&#xD;
          1. Active &gt; grade 2 diarrhoea&#xD;
&#xD;
          2. Prior allo- or autologous Stem Cell Transplant&#xD;
&#xD;
          3. Uncontrolled inter current illness or active infection&#xD;
&#xD;
          4. Pre-existing medical condition precluding treatment&#xD;
&#xD;
          5. Known hypersensitivity to any of the treatments or excipients&#xD;
&#xD;
          6. Second malignancy&#xD;
&#xD;
          7. Pregnant or breastfeeding women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Meriel Jenney</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chief Investigator</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bridget Shaw</last_name>
    <phone>0121 414 2996</phone>
    <email>farrms@trials.bham.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Joe Taylor</last_name>
    <phone>0121 414 3799</phone>
    <email>farrms@trials.bham.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Royal Marsden Hospital</name>
      <address>
        <city>Sutton</city>
        <state>Surrey</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julia Chisholm</last_name>
      <phone>020 8642 6011</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Manchester Children's Hospital</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 22, 2019</study_first_submitted>
  <study_first_submitted_qc>November 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 12, 2020</study_first_posted>
  <last_update_submitted>November 10, 2020</last_update_submitted>
  <last_update_submitted_qc>November 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhabdomyosarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dactinomycin</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

